Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

TG Therapeutics Launched FDA Approved Product BRIUMVI™ for Patients with Relapsing Forms of MS

January 27, 2023 0

TG Therapeutics TG Therapeutics (TGTX) is a commercial stage, biopharmaceutical company developing and commercializing novel treatments for …

Jazz Pharmaceuticals and Zymeworks Product Zanidatamab Advance the Treatment of HER2-expressing mGA

January 20, 2023 0

Jazz Pharmaceuticals and Zymeworks Inc Announce Results of Zanidatamab Jazz Pharmaceuticals (JAZZ) and Zymeworks Inc. (ZYME)

Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise

January 19, 2023 0

Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise Editas Medicine, Inc. (EDIT), announced that it has …

Ionis and Royalty Pharma Enter into a Royalty Agreement for Up to $1.1B

January 13, 2023 0

Ionis Pharmaceuticals and Royalty Pharma Ionis Pharmaceuticals (IONS) and Royalty Pharma plc (RPRX) announced that Royalty Pharma has …

Why Investors Have Enthusiasm for CureVac N.V.

January 10, 2023 0

CureVac N.V. in the News CureVac N.V. (CVAC) announced that after more than 10 years as …

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

January 5, 2023 1

CytomX and Moderna in the NEWS On January 05, 2023, CytomX Therapeutics (CTMX) and Moderna Inc (MRNA) announced a collaboration …

Stocks Outperforming Today

January 5, 2023 0

January 5, 2023 In Today's Down Market the stocks that are outperforming are as follows: Reata …

Promising Stocks in the First Two Trading Days of 2023

January 4, 2023 0

The Stock Market in the New Year It is still too early to tell how the …

Gilead Sciences – Still Way Undervalued

December 29, 2022 0

Prohost Letter #453 Gilead Sciences Still Way UNDERVALUED Finally, many analysts who happened to downgrade Gilead …

Why Kala Pharmaceuticals Stock is Soaring

December 28, 2022 0

Kala Pharmaceuticals Kala Pharmaceuticals (KALA) announced today that the U.S. FDA has accepted the investigational new drug …

A Note To Our Followers

December 23, 2022 2

Dear Friends and Followers, We confirm our optimism towards the future biotech firms that we selected …

Madrigal Pharmaceuticals and Akero Therapeutics: After Having No Treatment for NASH, We Now Have Two Products Expected to be Approved

December 19, 2022 0

Treatments for NASH Madrigal Pharmaceuticals (MDGL) is the second company after Akero Therapeutics (AKRO) to . …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

TG Therapeutics Launched FDA Approved Product BRIUMVI™ for Patients with Relapsing Forms of MS

Jazz Pharmaceuticals and Zymeworks Product Zanidatamab Advance the Treatment of HER2-expressing mGA

Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise

Ionis and Royalty Pharma Enter into a Royalty Agreement for Up to $1.1B

Why Investors Have Enthusiasm for CureVac N.V.

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Stocks Outperforming Today

Promising Stocks in the First Two Trading Days of 2023

Gilead Sciences – Still Way Undervalued

Why Kala Pharmaceuticals Stock is Soaring

A Note To Our Followers

Madrigal Pharmaceuticals and Akero Therapeutics: After Having No Treatment for NASH, We Now Have Two Products Expected to be Approved

What We Learned This Morning

Why IVERIC bio Rallied Today

Reata Pharmaceuticals Announces 3Q 2022 Financial Results and an Update on Clinical Development Programs

Searching for Biotech Firms with Novel Drugs That Reached Clinical-Stage or Were Granted Early Fast Track Designation

Acumen Pharmaceuticals: New Effort to Treat Alzheimer’s Disease Granted FDA Fast Track Designation

Gilead and MacroGenics Announce Oncology Collaboration to Develop Promising Bispecific Antibodies

Reata Pharmaceuticals: Good News for the Prohost Pick

Travere Therapeutics: Treating IgA Nephropathy and Focal Segmental Glomerulosclerosis